Last week the National Institute of Clinical Excellence (NICE) made public its initial review on inhaled insulin.
They suggested that inhaled insulin should only be made available through research trials in order to collect further information on cost effectiveness, clinical effectiveness and quality of life issues.
Medical Journal, The Lancet, today published its own views. They acknowledge that is is not suitable for everyone with diabetes and that there is a lack of evidence on the long term safety of inhaled insulin. However, they state,
"...it should be left to the individual physicians in discussions with their patients to make appropriate use of this new technology."
Diabetes UK has publicly urged NICE to reconsider its recommendations, taking into account the wishes of people with diabetes. We would also like to see further research to support the improvements made by using inhaled insulin on quality of life.
For further details on the pros and cons of inhaled insulin please see the updated fact sheet linked at the bottom of this page.
Diabetes UK will be formally collating responses to this initial review to feed back to NICE. If you would like to feed into this consultation process, we would recommend that you firstly read the attached fact sheet and then email@example.com your comments.
If you would like to comment directly to NICE please visithttp://www.nice.org.uk/page.aspx?o=305465before 10 May 2006.
A second announcement will then be made by NICE at the beginning of July.
Diabetes UK will continue to ensure that people are given unbiased information about inhaled insulin so that they can consider the recommendations in an informed way.